StemCell Institute(JP:7096)
Â¥640.000.00 (0.00%)
JP:7096
StemCell Institute financials statements
Â¥640.00
At close:0.00 (0.00%)
Want to see JP:7096 full AI Analyst Report?
StemCell Institute (7096) Ratios
0 Followers
StemCell Institute Ratios
JP:7096's free cash flow for Q4 2025 was ¥0.00. For the 2025 fiscal year, JP:7096's free cash flow was increased by ¥0.00 and operating cash flow was ¥0.00. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.17 | 1.20 | 1.20 | 1.32 | 1.37 |
| Quick Ratio | 1.16 | 1.19 | 1.19 | 1.31 | 1.36 |
| Cash Ratio | 0.63 | 0.74 | 0.76 | 0.97 | 1.15 |
| Solvency Ratio | 0.06 | 0.11 | 0.11 | 0.09 | 0.07 |
| Operating Cash Flow Ratio | 0.02 | 0.11 | 0.09 | 0.03 | 0.15 |
| Short-Term Operating Cash Flow Coverage | 1.04 | 6.96 | 158.74 | 74.77 | 0.00 |
| Net Current Asset Value | ¥ 263.26M | ¥ 283.76M | ¥ 664.58M | ¥ 1.03B | ¥ 1.07B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.06 | 0.07 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.18 | 0.20 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.15 | 0.16 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.12 | 0.14 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 3.03 | 2.86 | 2.43 | 2.53 | 2.48 |
| Debt Service Coverage Ratio | 3.84 | 7.53 | 191.49 | 241.24 | 0.00 |
| Interest Coverage Ratio | 37.20 | 348.18 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.06 | 0.04 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 47.46 | 50.79 | 1.05 | 0.67 | 0.00 |
| Net Debt to EBITDA | -6.21 | -3.86 | -5.31 | -8.24 | -11.35 |
| Profitability Margins | |||||
| Gross Profit Margin | 60.90% | 63.16% | 63.51% | 63.88% | 62.36% |
| EBIT Margin | 7.94% | 21.16% | 16.68% | 14.23% | 11.93% |
| EBITDA Margin | 13.52% | 25.95% | 21.52% | 19.25% | 17.37% |
| Operating Profit Margin | 7.21% | 15.62% | 16.68% | 14.23% | 12.74% |
| Pretax Profit Margin | 7.75% | 21.12% | 17.79% | 13.34% | 11.93% |
| Net Profit Margin | 5.55% | 14.40% | 12.53% | 9.47% | 7.50% |
| Continuous Operations Profit Margin | 4.66% | 14.40% | 12.53% | 9.47% | 7.50% |
| Net Income Per EBT | 71.59% | 68.20% | 70.46% | 70.99% | 62.91% |
| EBT Per EBIT | 107.46% | 135.17% | 106.66% | 93.75% | 93.66% |
| Return on Assets (ROA) | 1.92% | 5.13% | 4.75% | 3.41% | 2.56% |
| Return on Equity (ROE) | 5.81% | 14.68% | 11.55% | 8.62% | 6.36% |
| Return on Capital Employed (ROCE) | 5.64% | 13.08% | 14.87% | 12.50% | 10.49% |
| Return on Invested Capital (ROIC) | 3.33% | 8.74% | 10.46% | 8.87% | 6.60% |
| Return on Tangible Assets | 1.97% | 5.22% | 4.78% | 3.42% | 2.58% |
| Earnings Yield | 2.02% | 2.78% | 1.61% | 0.77% | 0.66% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.21 | 1.46 | 1.57 | 1.84 | 3.00 |
| Payables Turnover | 32.35 | 39.60 | 25.65 | 25.03 | 22.39 |
| Inventory Turnover | 20.35 | 19.36 | 21.42 | 19.20 | 16.70 |
| Fixed Asset Turnover | 2.04 | 2.32 | 3.73 | 3.23 | 2.75 |
| Asset Turnover | 0.35 | 0.36 | 0.38 | 0.36 | 0.34 |
| Working Capital Turnover Ratio | 3.44 | 3.33 | 2.66 | 1.87 | 2.11 |
| Cash Conversion Cycle | 309.37 | 259.82 | 235.82 | 202.87 | 127.31 |
| Days of Sales Outstanding | 302.71 | 250.18 | 233.02 | 198.44 | 121.77 |
| Days of Inventory Outstanding | 17.94 | 18.85 | 17.04 | 19.01 | 21.85 |
| Days of Payables Outstanding | 11.28 | 9.22 | 14.23 | 14.58 | 16.30 |
| Operating Cycle | 320.65 | 269.03 | 250.05 | 217.46 | 143.62 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 7.28 | 45.67 | 32.66 | 9.73 | 46.33 |
| Free Cash Flow Per Share | -33.25 | -0.99 | 12.98 | 3.88 | 26.14 |
| Dividend Paid and CapEx Coverage Ratio | 0.18 | 0.64 | 1.66 | 1.66 | 2.30 |
| Capital Expenditure Coverage Ratio | 0.18 | 0.98 | 1.66 | 1.66 | 2.30 |
| Operating Cash Flow Coverage Ratio | 0.16 | 0.90 | 31.03 | 14.47 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.03 | 0.17 | 0.13 | 0.05 | 0.26 |
| Free Cash Flow Yield | -4.34% | -0.07% | 0.69% | 0.15% | 1.30% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 49.61 | 36.02 | 61.94 | 130.13 | 152.05 |
| Price-to-Sales (P/S) Ratio | 2.75 | 5.19 | 7.76 | 12.32 | 11.41 |
| Price-to-Book (P/B) Ratio | 2.88 | 5.29 | 7.15 | 11.21 | 9.66 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -23.04 | -1374.66 | 144.87 | 647.99 | 76.78 |
| Price-to-Operating Cash Flow Ratio | 105.23 | 29.72 | 57.57 | 258.55 | 43.33 |
| Price-to-Earnings Growth (PEG) Ratio | -0.84 | 1.47 | 1.10 | 2.80 | 1.44 |
| Enterprise Value Multiple | 14.15 | 16.13 | 30.77 | 55.78 | 54.36 |
| Enterprise Value | 5.38B | 11.22B | 16.43B | 22.45B | 16.82B |
| EV to EBITDA | 14.15 | 16.13 | 30.77 | 55.78 | 54.36 |
| EV to Sales | 1.91 | 4.19 | 6.62 | 10.74 | 9.44 |
| EV to Free Cash Flow | -16.01 | -1109.39 | 123.55 | 564.58 | 63.53 |
| EV to Operating Cash Flow | 73.12 | 23.98 | 49.10 | 225.27 | 35.85 |
| Tangible Book Value Per Share | 282.10 | 243.66 | 258.72 | 221.93 | 205.29 |
| Shareholders’ Equity Per Share | 265.58 | 256.59 | 262.78 | 224.33 | 207.73 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.40 | 0.32 | 0.30 | 0.29 | 0.37 |
| Revenue Per Share | 278.38 | 261.60 | 242.15 | 204.10 | 175.93 |
| Net Income Per Share | 15.44 | 37.67 | 30.35 | 19.33 | 13.20 |
| Tax Burden | 0.72 | 0.68 | 0.70 | 0.71 | 0.63 |
| Interest Burden | 0.98 | 1.00 | 1.07 | 0.94 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 |
| SG&A to Revenue | 0.54 | 0.48 | 0.38 | 0.40 | 0.39 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.47 | 1.21 | 1.08 | 0.50 | 2.21 |
Currency in JPY

